Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
暂无分享,去创建一个
Z. Ram | S. Melmed | I. Shimon | A. Gertych | Y. Greenman | N. Stern | I. Yaish | E. Robenshtok | T. Jonas-Kimchi | N. Sagiv | O. Cooper | X. Yuan | Ilan Shimon | Nadav Sagiv | Odelia Cooper | Xiaopu Yuan | Arkadiusz Gertych | Zvi Ram
[1] I. Bryngelsson,et al. Excess Mortality in Women and Young Adults With Nonfunctioning Pituitary Adenoma: A Swedish Nationwide Study. , 2015, The Journal of clinical endocrinology and metabolism.
[2] L. Kasuki,et al. Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy , 2015, Clinical endocrinology.
[3] M. Fleseriu. Medical treatment of Cushing disease: new targets, new hope. , 2015, Endocrinology and metabolism clinics of North America.
[4] Sarah E Mayson,et al. Silent pituitary adenomas. , 2015, Endocrinology and metabolism clinics of North America.
[5] P. Chanson,et al. Expert consensus document: A consensus on the medical treatment of acromegaly , 2014, Nature Reviews Endocrinology.
[6] C. Benbassat,et al. Clinical course and outcome of nonfunctioning pituitary adenomas in the elderly compared with younger age groups. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[7] W. Drake,et al. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. , 2014, The Journal of clinical endocrinology and metabolism.
[8] J. Kros,et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. , 2013, The Journal of clinical endocrinology and metabolism.
[9] L. Naves,et al. Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas , 2013, Pituitary.
[10] S. Yamada,et al. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels. , 2012, European journal of endocrinology.
[11] M. Beranek,et al. Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas , 2012, Pituitary.
[12] Q. Zhuge,et al. Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas , 2012, Neurological Sciences.
[13] Ferdinand Roelfsema,et al. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis , 2011, Pituitary.
[14] Manish K Aghi,et al. Dopamine agonist-resistant prolactinomas. , 2011, Journal of neurosurgery.
[15] V. Montori,et al. Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline , 2011, The Journal of clinical endocrinology and metabolism.
[16] N. Karavitaki,et al. Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? , 2010, European journal of endocrinology.
[17] P. Chanson,et al. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. , 2010, European journal of endocrinology.
[18] Yan Zeng,et al. Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior , 2010, Journal of Neuro-Oncology.
[19] R. Kineman,et al. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.
[20] A. Faggiano,et al. Medicaltherapyforclinicallynon-functioning pituitary adenomas , 2008 .
[21] M. Culler,et al. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. , 2008, Endocrine-related cancer.
[22] M. Molitch. Nonfunctioning pituitary tumors and pituitary incidentalomas. , 2008, Endocrinology and metabolism clinics of North America.
[23] M. Losa,et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. , 2008, Journal of neurosurgery.
[24] A. Antonini,et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. , 2007, The New England journal of medicine.
[25] E. Krenning,et al. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? , 2006, European journal of endocrinology.
[26] S. Shalet,et al. Hypopituitarism As a Consequence of Brain Tumours and Radiotherapy , 2006, Pituitary.
[27] Y. Segev,et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth , 2005, Clinical endocrinology.
[28] L. Cavallo,et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. , 2004, The Journal of clinical endocrinology and metabolism.
[29] P. Chanson,et al. Non-functioning pituitary adenomas. , 2005, Journal of endocrinological investigation.
[30] R. Paschke,et al. Minor Tumour Shrinkage in Nonfunctioning Pituitary Adenomas by Long-Term Treatment with the Dopamine Agonist Cabergoline , 2001, Pituitary.
[31] A. Klibanski,et al. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. , 2003, The Journal of clinical endocrinology and metabolism.
[32] B. Norrving,et al. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. , 2002, The Journal of clinical endocrinology and metabolism.
[33] D Barnes,et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol , 2000, Journal of clinical pathology.
[34] H. Magdelenat. The Receptor and Biomarker Study Group of the EORTC , 2000 .
[35] Bates,et al. Radiotherapy for non‐functioning pituitary tumours , 1998 .
[36] C. Matula,et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. , 1993, Neurosurgery.
[37] S. Lamberts,et al. Bromocriptine increasingly suppresses the in vitro gonadotropin and alpha-subunit release from pituitary adenomas during long term culture. , 1990, The Journal of clinical endocrinology and metabolism.
[38] J. Bevan,et al. NON‐FUNCTIONING PITUITARY ADENOMAS DO NOT REGRESS DURING BROMOCRIPTINE THERAPY BUT POSSESS MEMBRANE‐BOUND DOPAMINE RECEPTORS WHICH BIND BROMOCRIPTINE , 1986, Clinical endocrinology.